Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novo Nordisk receives FDA approval for basal insulin Awiqli
It is indicated as an adjunct to exercise and diet for improving glycaemic control. The FDA’s decision is based on data from the ONWARDS Phase IIIa clinical programme,
It is indicated as an adjunct to exercise and diet for improving glycaemic control. The FDA’s decision is based on data from the ONWARDS Phase IIIa clinical programme,
The acquisition will provide access to Exl-111, a half-life extended, high-affinity anti-IgE antibody currently in Phase I clinical trials. Designed as an advanced extension of the established biology
The partnerships aim to apply AI within scientifically validated modelling workflows and define scalable, next-generation approaches throughout the drug development life cycle. The programmes will use Simulations Plus
The initiative will combine Cognito Therapeutics’ investigational Spectris technology platform with the clinical infrastructure of Ochsner Health to explore innovative approaches to brain health across urban and rural
Daiichi Sankyo will utilise Tempus’ foundation models such as PRISM2, which integrates pathology images and clinical data to generate diagnostic and predictive insights. The partnership will combine Daiichi
Cardiac amyloidosis is a progressive condition where misfolded proteins accumulate in the heart muscle, often leading to heart failure. There are two main types of cardiac amyloidosis: wild-type
Under the agreement, Quotient will receive $20m upfront and could also earn up to $2.2bn through regulatory, development, and commercial milestone payments. Quotient’s somatic genomics approach analyses naturally
This collaboration is also aimed at expediting early-phase clinical trials and delivering new therapies to patients. It will leverage both organisations’ expertise to advance healthcare innovation. Each partner
The agreement grants Sanofi worldwide rights to KT501, which is under evaluation in a first-in-human clinical trial for rheumatoid arthritis, focusing on tolerability, safety, pharmacodynamics, and pharmacokinetics. Under
This approval covers adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) who have carcinoma in situ (CIS), with or without papillary tumours. The authorisation follows a review